Hematology Division
Alphabetical list (active faculty):   
Elaine M. Majerus

Elaine M. Majerus, MD, PhD


Department of Medicine

Hematology Division

Clinical Interests

  • Hemophilia and bleeding disorders
  • Thrombosis
  • Paroxysmal nocturnal hemoglobinuria
  • Atypical hemolytic uremic syndrome


  • 314-362-8814 (office)
  • 314-362-8813 (fax)
  • Hematology Division
    Mail Stop 8125-0022-01
    Washington University
    660 South Euclid Avenue
    St. Louis, MO 63110
  • Suite 1101 Wohl Hospital (office)


My work focuses on the care of patients with hematological disorders and clinical research in sickle cell disease, thrombotic disorders including thrombotic microangiopathies, and hemophilia. In clinic, I see patients with a broad spectrum of hematology problems from anemia, thrombotic microangiopathies, bleeding disorders, and clotting disorders. I see patients at the Center for Advanced Medicine as well as at Barnes-Jewish West County Hospital and Siteman South County Clinic.

My clinical research is focused on bleeding and blood clotting disorders and sickle cell disease. In conjunction with Alexion Pharmaceuticals, I have registries open to enroll patients with atypical hemolytic uremic syndrome and paroxysmal nocturnal hemoglobinuria to learn more about the presentation and outcomes of these rare disorders.

We also collect samples from those with a history of blood clots through a thrombotic banking study that stores blood samples for future research projects. These samples are available for sequencing in collaboration with Dr. John Atkinson to identify mutations that may be associated with thrombotic disorders. We hope to better understand the causes of clotting disorders and better tailor treatments.

I am involved in sickle cell disease research with two clinical trials that are seeking ways to decrease inflammation associated with sickle cell vaso-occlusive crisis. We are currently enrolling patients in a Phase 2 study of regadenoson in sickle cell vaso-occlusive crisis. This drug has been shown to decrease inflammation through inhibition of iNKT cell activity. We are also enrolling patients in a Phase 1 study of a monoclonal antibody directed against iNKT cells. This study is seeking the optimal dose of drug that will decrease iNKT cells without dose-limiting toxicities.

Last, Washington University is a federally-designated Hemophilia Treatment Center. We provide exceptional care to both pediatric and adult patients with bleeding and blood clotting disorders. In conjunction with our Hemophilia Treatment Center, we are enrolling patients in the American Thrombosis and Hemostasis Network database of those with bleeding and blood clotting disorders. This database consists of demographic information and outcomes data on patients and will be used to further research into these disorders. We also are enrolling patients in the My Life Our Future study that genotypes those with hemophilia A and B to identify the mutation responsible for their disease.